Результаты поиска

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.

ObjectiveTwo phase I studies of darinaparsin including Japanese and Korean patients with relapsed/refractory peripheral T-cell lymphoma were performed to evaluate its safety (primary purpose), efficacy and pharmacokinetic profile (ClinicalTrials.gov: NCT01435863 and NCT01689220).MethodsPatients received intravenous darinaparsin for 5 consecutive days at 200 mg/m2/day in 4-week cycles, 300 mg/m2/day in 4-week cycles or 300 mg/m2/day in 3-week cycles.ResultsSeventeen Japanese and 6 Korean patients were enrolled and treated. Drug-related adverse events developed in 18 patients (78%). Dose-limitin

Совпадение в полном тексте источника
… Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117:368–79. 26. Willenbrock K, Bräuninger A, Hansmann ML. …

Токсичность CAR-T, биконкретных антител и антителных соединений в Множественной миеломе: практический подход к уменьшению рисков и управлению ими.

Антигены созревания B-клеток (BCMA), группа рецепторов с белковым сцеплением C 5 Член группы D (GPRC5D) под руководством иммунотерапии, продуктов химерика антигенного рецептора Т-клестера (CAR-T), лиц, занимающихся деятельностью в двух конкретных Т-клетках (BsAbs), и лиц, занимающихся антителными препаратами (ADC), изменил управление MM. В настоящее время их внедрение выходит за рамки высших центров после внесения изменений в УЛХ для обеспечения безопасности CAR-T и быстрого внедрения недр, пригодных для общинной доставки. Поэтому врачи, находящиеся вне специализированных центров, должны быть

Сопоставление клинических результатов между пиелоперфюзелями и микроволновой абсорбацией почечных клеток.

Справочная информация: Сопоставимость характерна для пациентов с множественным склерозом (МС), что повышает сложность лечения заболеваний и экономического бремени и ухудшает их прогноз и качество жизни. Не хватает реальных данных, позволяющих сопоставлять коморбиды и модели множественной смертности, характерные для лиц, охваченных системой страхования на коммерческой основе, и лиц, охваченных системой " Medicare " . Цель: Оценка структуры коморбидности и многоженства среди пациентов с НР в американской компании " Компромисс " и " Медикэр аппетит " . Методы: Это ре

Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.

Sepsis is a frequent complication in immunosuppressed cancer patients and hematopoietic stem cell transplant recipients that is associated with high morbidity and mortality rates. The worldwide emergence of antimicrobial resistance is of special concern in this population because any delay in starting adequate empirical antibiotic therapy can lead to poor outcomes. In this review, we aim to address: (1) the mechanisms involved in the development of sepsis and septic shock in these patients; (2) the risk factors associated with a worse prognosis; (3) the impact of adequate initial empirical ant

Совпадение в полном тексте источника
… Some lymphoproliferative disorders may also cause hypogammaglobulinemia, and the compression of anatomic structures and/or tissue infiltration by malignant cells can diminish local defense mechanisms. …

CAR T-cell therapy and the onco-nephrologist.

Cell therapy, specifically the revolutionary chimeric antigen receptor (CAR) T-cell therapy, has transformed the landscape of oncology, making substantial strides in practical treatment approaches. Today, established guidelines for diseases such as lymphomas, myelomas, and leukemias actively advocate the utilization of these once-unconventional therapies. The practical impact of these therapies is underscored by their unparalleled efficacy, reshaping the way we approach and implement treatments in the realm of oncology. However, CAR T-cell therapy, with its performance in anti-tumor aggression

Совпадение в полном тексте источника
… Management of immunosuppression in post-transplant lymphoproliferative disorders treated with CAR T cells. Br J Haematol. (2024) BJB 2024;000:1-5. doi: 10.1111/bjh.19355 …

Fractures and survival in multiple myeloma: results from a population-based study.

Multiple myeloma causes lytic bone lesions and fractures. The impact of fractures on multiple myeloma (MM) survival is unclear. The aim of this study was to evaluate the effect of fractures on survival in MM using data from MM patients diagnosed in Sweden in the years 1990-2013, identified from the Swedish Cancer Registry. Information on date of birth, MM diagnosis, fractures, and death was collected from central registries. A Cox regression model was used to compare survival in patients with and without a fracture at MM diagnosis and another Cox model was used with fracture as a time-dependen

Stem Cells and Organ Transplantation: Resetting Our Biological Clocks

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Evidence for the use of intravenous immunoglobulins--a review of the literature.

Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel

Platelet Transfusion for Patients with Cancer: An Update.

BackgroundPlatelet transfusion is essential for preventing and treating hemorrhage in oncology patients and can markedly improve quality of life and survival. However, access to platelet concentrates is often limited by global shortages and logistical constraints, especially in low-resource settings.SummaryMaintaining product quality requires stringent donor screening, pathogen-reduction technologies, and optimized storage conditions to preserve hemostatic function and reduce adverse reactions. Common transfusion-related complications (e.g., alloimmunization, non-hemolytic reactions, and circu

Monoclonal gammopathy of increasing significance: time to screen?

Monoclonal gammopathy (MG) is a frequently detected clonal B-cell or plasma-cell disorder. Importantly, every multiple myeloma (MM) case is preceded by MG. Although clinical algorithms now allow earlier treatment of patients with biomarkers of malignancy before MM-induced tissue damage (CRAB) occurs, most patients are still diagnosed late. It is important to revisit how MG should be managed in clinical practice and whether screening is required. As the prevalence of MG and other medical co-morbidities both rise with increasing age, the degree of contribution of MG to disease states other than

Совпадение в полном тексте источника
… After 3 years of follow-up, MG patients in the intensive follow-up arm of the study had significantly higher detection rates of lymphoproliferative disorders, specifically smoldering WM, SMM and MM, 84 demonstrating that early detection of these malignancies through screening is possible. …

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.

BACKGROUND: Plasma cell myeloma (PCM) is a neoplasm of terminally differentiated B lymphocytes with molecular heterogeneity. Although therapy-related myeloid neoplasms are common in plasma cell myeloma patients after chemotherapy, transdifferentiation of plasma cell myeloma into myeloid neoplasms has not been reported in literature. Here we report a very rare case of myeloid neoplasm transformed from plasma cell myeloma. CASE PRESENTATION: A 60-year-old man with a history of plasma cell myeloma with IGH-MAF gene rearrangement and RAS/RAF mutations developed multiple soft tissue lesions one ye

Совпадение в полном тексте источника
… Ambrosio MR Rocca BJ Ginori A Mourmouras V Amato T Vindigni C Lazzi S Leoncini L A look into the evolution of Epstein-Barr virus-induced lymphoproliferative disorders: a case study Am J Clin Pathol 2015 144 5 817 822 10.1309/AJCP2G0VKTKPNPRR 26486748 …

Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities.

Pruritus is the most frequently described symptom in dermatology and can significantly impair the patient's quality of life. In 10-50% of adults with persistent pruritus, it can be an important dermatologic clue for the presence of a significant underlying systemic disease such as renal insufficiency, cholestasis, hematologic disorder, or malignancy (Etter and Myers, 2002; Zirwas and Seraly, 2001). This review describes the presence of pruritus in different systemic diseases. It is quite important to discover the cause of pruritus for providing relief for the patients experiencing substantial

Совпадение в полном тексте источника
… Pruritus in HIV may occur with skin infections, infestations, papulosquamous disorders, photodermatitis, xerosis, drug reactions, and occasionally lymphoproliferative disorders such as cutaneous T cell lymphoma or without primary dermatosis [ 83 ]. …

Трансплантация гемопоэтических стволовых клеток при множественной миеломе в Казахстане: десятилетний одноканальный опыт.

Цель. Настоящее исследование было направлено на оценку лечебных схем и клинических исходов у пациентов с множественной миеломой, получавших лечение в крупном онкологическом центре Казахстана в период 10 лет. Методы. Эта ретроспективное наблюдательное исследование проанализировало данные 261 пациента с множественной миеломой, получавших лечение в Национальном исследовательском онкологическом центре, Астана, с 2010 по 2021 год. Социodemографические и клинические характеристики, режимы лечения и исходы выживания были оценены на основе данных электронных медицинских записей. Результаты: Большинств

Concurrent B-cell acute lymphoblastic leukemia and plasma cell neoplasm with plasmablastic features supporting divergent evolution from a shared precursor: a case report.

BACKGROUND: B-cell malignancies comprise a biologically diverse group of neoplasms, with only rare reports describing the co-occurrence of two distinct lymphoid entities. While concurrent presentation of mature B-cell neoplasms has been documented, the simultaneous occurrence of B-cell acute lymphoblastic leukemia (B-ALL) and plasma cell neoplasm (PCN) has previously been reported rarely. Such cases may provide insight into the clonal architecture and evolutionary pathways underlying lymphoid malignancies. CASE PRESENTATION: We report a 76-year-old man presenting with cytopenias and leukocyto

Совпадение в полном тексте источника
… Immunophenotyping of Acute Leukemia and Lymphoproliferative Disorders: A Consensus Proposal of the European Leukemianet Work Package 10. Leukemia. (2011) 25(4):567–74. doi: 10.1038/leu.2010.312 13. Lang F, Wojcik B, Rieger MA. …

Использование реальных доказательств в США. Управление по контролю за продуктами питания и лекарственными препаратами и Европейское агентство по лекарственным препаратам утверждают онкологические продукты, поддерживаемые односторонними испытаниями (Advisory and Drug Argency and the European Medicals Agency (European Medicals Agency)2022-2025).

ВВЕДЕНИЕ: Усилился интерес регулирующих органов к реальным доказательствам (РВЭ) в дополнение к односторонним испытаниям (САТ) в области онкологии, однако по-прежнему отсутствует полное понимание того, как Управление по контролю за продуктами питания и лекарствами (ДПП) и Европейское агентство по медицине (ЕМА) оценивают такие доказательства. ЦЕЛЬ: Всеобъемлющая оценка недавних решений по онкологии, в которых СТА поддерживаются РВЭ, с описанием обратной связи по вопросам нормативного регулирования, методологических подходов, роли РВЭ в процессе принятия решений. Мы рассмотрели новые прикладные

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.

Carfilzomib, a selective proteasome inhibitor approved in the USA in 2012, is a single agent for relapsed and refractory multiple myeloma. Carfilzomib is administered as a 2-10-minute infusion on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle at a starting dose of 20 mg/m(2) for cycle 1 and a target dose of 27 mg/m(2) thereafter. In the pivotal Phase II study (PX-171-003-A1), carfilzomib 20/27 mg/m(2) provided durable responses in a heavily pretreated population with relapsed and refractory multiple myeloma (n=266), with an overall response rate of 22.9% and a median duration of response of 7.8

Dural Lymphomas Unmasked: A Narrative Review of Extra-Axial Mimics and a Pragmatic Diagnostic Decision Algorithm.

Dural-based lymphomas are rare extranodal non-Hodgkin lymphomas that span from indolent primary dural entities, most commonly the extranodal marginal zone (mucosa-associated lymphoid tissue) lymphoma, to aggressive variants that are primary or represent secondary involvement from systemic lymphoma. They overlap radiologically with benign meningiomas, dural metastases, and immune-mediated pachymeningitis, creating a risk of anchoring bias, delayed diagnosis, and unnecessarily extensive resections when limited tissue sampling would be sufficient for diagnosis. We conducted a structured narrative

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.

Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease. There is a critical need to identify patients in this population who benefit from renal transplantation. This multicenter, observational study from five countries includes 237 patients with AL amyloidosis who underwent renal transplantation between 1987 and 2020. With a median follow-up of 8.5 years, the median overall survival from renal transplantation was 8.6 years and was significantly lon

Biphosphonates-associated osteonecrosis of the jaw: the role of gene-environment interaction.

Biphosphonate (BPN) are widely used in clinics to treat metastatic cancer and osteoporosis thus representing a problem not only for patients but also for workers involved in their preparation and administration. A similar exposure occurred years ago in match-making workers undergoing bone alterations similar to those consequent to BPN exposure. Osteonecrosis of the jaw (ONJ) is a main adverse effect related to BPN administration, which is performed in millions of patients worldwide for osteoporosis and cancer therapy, thus representing an emerging problem in public health. In susceptible patie

Совпадение в полном тексте источника
… Endogenous risk factors and oral osteonecrosis Systemic and local risk factors ONJ may be associated with a number of different predisposing systemic conditions such as haemoglobinopathies, coagulopathies, lymphoproliferative disorders, Paget's disease, phosphorous exposure, and local conditions of …

The Role of Intravesicular Proteins and the Protein Corona of Extracellular Vesicles in the Development of Drug-Induced Polyneuropathy.

Extracellular vesicles (EVs) as membrane structures of cellular origin participating in intercellular communication are involved in the molecular mechanisms of the development of various variants of polyneuropathy. Taking into account the increasing role of the protein corona of EVs and protein-protein interactions on the surface of EVs in the pathogenesis of various diseases, we focused our attention in this review on the role of intravesicular proteins and the protein corona of EVs in the development of chemotherapy-induced polyneuropathy (CIPN). It has been shown that EVs are effectively in